Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 5,359 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AIDS Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Project Power: An HIV Risk Reduction Intervention for Black Men Who Have Sex With Men and Women (BMSM/W)

NCT01376895
View directory record Official record
Conditions
Unsafe Sex, Risk Reduction
Interventions
PROJECT POWER, Power Health
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 21, 2026, 4:00 AM EDT
Completed No phase listed Observational

Lung HIV Disease in a Large Cohort-Pitt

NCT01326572
View directory record Official record
Conditions
Pulmonary Disease, HIV, Emphysema
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years · Male only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Not applicable Interventional Results available

Developing a Trauma-focused Intervention for Older Adults Living With HIV

NCT05287230
View directory record Official record
Conditions
Trauma, Hiv, Aging
Interventions
CoSHA (Coping with childhood Sexual Abuse, HIV, and Aging), Control
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
50 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 21, 2026, 4:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Peer Behavioral Activation Utilization to Improve Substance Use and HIV Outcomes in People Receiving Long Acting Injectable-PrEP/ART (PUSH)

NCT06501781
View directory record Official record
Conditions
HIV Infections, Substance Use
Interventions
Peer Activate-LAI, Standard of Care HIV treatment or prevention with LAI-PrEP/ART
Behavioral · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 3 Interventional Results available

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

NCT00112047
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
5
States / cities
Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

NCT06033547
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Formulation F, Cabotegravir Formulation G
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss

NCT00000925
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Optimune oral nutritional supplement
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

NCT03917420
View directory record Official record
Conditions
HIV/AIDS
Interventions
Tenofovir 300Mg Oral Tablet, Emtricitabine 200 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Not applicable Interventional

Safer Choices 2 - HIV, STD, & Pregnancy Prevention Program

NCT00223314
View directory record Official record
Conditions
HIV, Sexually Transmitted Diseases, Pregnancy, HIV Infections
Interventions
HIV, STD, Pregnancy Prevention Curriculum
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 21, 2026, 4:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments

NCT01445314
View directory record Official record
Conditions
HIV, Brain Tumors, Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month and older
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Familias Unidas: Preventing Substance Abuse in Hispanic Youth

NCT01038206
View directory record Official record
Conditions
Prevention, Family Function, Substance Use, Sexual Behavior
Interventions
Familias Unidas
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
12 Years and older
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS

NCT00118378
View directory record Official record
Conditions
HIV Infections, Fatigue
Interventions
Modafinil, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

NCT00339040
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 12 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
32
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Not applicable Interventional

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

NCT00015691
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions
Metformin hydrochloride, Rosiglitazone maleate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

NCT00799058
View directory record Official record
Conditions
HIV-1 Infections
Interventions
dapivirine 4789, dapivirine gel 4759, Drug placebo
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
5
States / cities
Birmingham, Alabama • Torrance, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 21, 2026, 4:00 AM EDT
Recruiting Not applicable Interventional

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

NCT06263426
View directory record Official record
Conditions
Hiv
Interventions
HIV D-/R+
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 4:00 AM EDT
Completed No phase listed Observational

Typology of Adherence in Adolescents: Phase II

NCT00106678
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 2 Interventional Results available

Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease

NCT02339415
View directory record Official record
Conditions
Inflammation, Coagulation, HIV Infection
Interventions
Edoxaban 30mg daily, Matching placebo
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

NCT00951015
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572, efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
13
States / cities
Phoenix, Arizona • Bakersfield, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

NCT04223778
View directory record Official record
Conditions
HIV Infection
Interventions
DOR/ISL, ART
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Ft. Pierce, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 3 Interventional Results available

VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients

NCT00561925
View directory record Official record
Conditions
HIV Infections
Interventions
nevirapine IR, nevirapine XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 21, 2026, 4:00 AM EDT
Completed No phase listed Observational

A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection

NCT00001117
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
42
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2008 · Synced Oct 21, 2026, 4:00 AM EDT
Recruiting Not applicable Interventional

High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV

NCT05965518
View directory record Official record
Conditions
HIV, Arterial Stiffness, Cognitive Dysfunction
Interventions
High-Intensity Interval Training, Continuous Moderate Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 4:00 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

NCT00392834
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, pegfilgrastim, rituximab, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, liposomal cytarabine, methotrexate, therapeutic hydrocortisone, vincristine sulfate
Biological · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 21, 2026, 4:00 AM EDT